Skip Navigation


European Heart Journal Advance Access originally published online on October 17, 2005
European Heart Journal 2006 27(1):114-115; doi:10.1093/eurheartj/ehi589
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/1/114    most recent
ehi589v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hertog, M. G.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hertog, M. G.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Workshop on CV prevention with a focus on metabolic syndrome and surrogate markers

Taskforce 1 of the Cardiovascular Round Table, European Society of Cardiology: Executive Summary Report

Michaël G.L. Hertog* on behalf of Taskforce 1

European Society of Cardiology, Sophia Antipolis, France

Received 29 August 2005; accepted 22 September 2005; online publish-ahead-of-print 17 October 2005.

* Corresponding author. E-mail address: mhertog@escardio.org

The first 10% of the full text of this article appears below.

On 9–10 June 2005, the European Society of Cardiology invited experts from academia, industry, and regulatory agencies to discuss the development of drugs in metabolic syndrome and the use of surrogate endpoints in clinical cardiovascular research. The metabolic syndrome is a relatively new clinical entity, resulting from the clustering of a number of processes, such as hypertension, glucose intolerance, and dyslipidaemia, linked to abdominal obesity, i.e. visceral fat excess. However, . . . [Full Text of this Article]

List of attendees

Acknowledgement


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
N. Galie, A. Manes, M. Palazzini, L. Negro, S. Romanazzi, and A. Branzi
Pharmacological impact on right ventricular remodelling in pulmonary arterial hypertension
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H68 - H74.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. H. Revkin, C. L. Shear, H. G. Pouleur, S. W. Ryder, and D. G. Orloff
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
Pharmacol. Rev., March 1, 2007; 59(1): 40 - 53.
[Abstract] [Full Text] [PDF]